Current Evidence on the Use of Calcitonin Gene-Related Peptide-Targeting Therapies in Children and Adolescents.
- 1Benioff Children's Hospital-Child & Adolescent Headache Program, University of California-San Francisco, San Francisco, California, USA. [email protected].
- 2Benioff Children's Hospital-Child & Adolescent Headache Program, University of California-San Francisco, San Francisco, California, USA.
Abstract
Purpose of review
This is a narrative review to summarize current evidence on use of therapies targeting calcitonin gene-related peptide (CGRP) for children and adolescents with headache disorders.Recent findings
The CGRP-targeting therapies have been used in adults for prevention of migraine since 2018. There is one randomized controlled trial (RCT) published on fremanezumab in children age 6-17 years old which showed favorable outcome as a preventive treatment for episodic migraine. Several real-world evidence (RWE) studies report on use of CGRP-targeting therapies in patients younger than 18 years old. Several clinical trials are pending for other CGRP-targeting therapies.Conclusion
There is a small number of RWE studies and one RCT study that shows that CGRP-targeting therapies have potential to be beneficial and safe to use in children and adolescents with headache disorders. Future clinical trials, once completed, will further shed light on efficacy and safety of CGRP-targeting therapies.
Related
- From Lab to App (and Back): A Conceptual Framework for Evidence-Based Digital Mental Health Interventions in Children and Adolescents
- Mental health outcomes following COVID-19- associated caregiver loss in children and adolescents: a six-year evidence gap
- Treatment of growth hormone deficiency with long-acting growth hormones in children, adolescents and adults: Clinical evidence and practical considerations
- Active commuting to school and physical activity participation in children and adolescents: evidence from a large cross-sectional study in Greece
- Efficacy, Immunogenicity, Safety, and Evidence Independence of CYD-TDV and TAK-003 Dengue Vaccines in Children and Adolescents: A Systematic Review and Meta-Analysis.
BibTeX
@article{shin2026current,
title = {{Current Evidence on the Use of Calcitonin Gene-Related Peptide-Targeting Therapies in Children and Adolescents.}},
author = {Lauren Shin and Ryan Moon and Amy Gelfand},
journal = {Current pain and headache reports},
year = {2026},
month = oct,
doi = {10.1007/s11916-026-01567-4},
url = {https://europepmc.org/article/MED/42873441},
note = {CC BY},
}
RIS
TY - JOUR
TI - Current Evidence on the Use of Calcitonin Gene-Related Peptide-Targeting Therapies in Children and Adolescents.
AU - Lauren Shin
AU - Ryan Moon
AU - Amy Gelfand
PY - 2026
DA - 2026/10/14
JO - Current pain and headache reports
DO - 10.1007/s11916-026-01567-4
UR - https://europepmc.org/article/MED/42873441
AB - Purpose of review This is a narrative review to summarize current evidence on use of therapies targeting calcitonin gene-related peptide (CGRP) for children and adolescents with headache disorders.Recent findings The CGRP-targeting therapies have been used in adults for prevention of migraine since 2018. There is one randomized controlled trial (RCT) published on fremanezumab in children age 6-17 years old which showed favorable outcome as a preventive treatment for episodic migraine. Several real-world evidence (RWE) studies report on use of CGRP-targeting therapies in patients younger than 18 years old. Several clinical trials are pending for other CGRP-targeting therapies.Conclusion There is a small number of RWE studies and one RCT study that shows that CGRP-targeting therapies have potential to be beneficial and safe to use in children and adolescents with headache disorders. Future clinical trials, once completed, will further shed light on efficacy and safety of CGRP-targeting therapies.
SN - 1531-3433
SN - 1534-3081
ER -